Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.

Current atherosclerosis reports - 1 Sept 2010

Davignon Jean, Dubuc Geneviève, Seidah Nabil G

Abstract excerpt

Pro-protein-convertase-subtilisin-kexin-9 (PCSK9) enhances the degradation of the low-density lipoprotein receptor (LDLR) that plays a major role in cholesterol homeostasis. Recent advances have revealed a large number of genetic variants of PCSK9 that may modulate plasma cholesterol levels either positively or negatively, therefore influencing the risk of atherosclerosis. Recognition of these mutants may have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Atherosclerosis
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Risk Factors

Share to Serine Endopeptidases

Source

Identifiers

PMID: 20623344
DOI: 10.1007/s11883-010-0123-6

Genes

PCSK9
LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.PMID 20623344Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

PCSK9 gene mutations and low-density lipoprotein cholesterol.Semantic proximity Read ↗

Unravelling the functional significance of PCSK9.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.Semantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.